| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/26/2001 | CN1314168A Paste for eradicating liver disease and preparing method |
| 09/26/2001 | CN1314167A Addiction giving up cigarette and its formula |
| 09/26/2001 | CN1314165A Ointment type external medicine |
| 09/26/2001 | CN1314160A Oral pill for curing diabetes and its complication |
| 09/26/2001 | CN1314151A Use of AFMK in preparing medicine with free radical cloaning function |
| 09/26/2001 | CN1314147A Superfine safflower powder and producing method |
| 09/26/2001 | CN1314146A Supercritical CO2 solvent-resistant device for producing nanometer material |
| 09/26/2001 | CN1071759C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and use thereof |
| 09/26/2001 | CN1071576C External application medicinal bag for curing cancerbus ache and incision ache after operation and its preparing method |
| 09/26/2001 | CN1071570C Extended release, film-coated table of astemizole and pseudoephedrine |
| 09/25/2001 | US6294582 Methods for treatment of asthma using S-oxybutynin |
| 09/25/2001 | US6294579 Method for improving delivery of tyrosine supplementation |
| 09/25/2001 | US6294550 Treatment of female sexual dysfunction |
| 09/25/2001 | US6294548 Mixture of indazole, preservative and benzyl alcohol anti-emetic, particularly in the treatment of cytotoxic agent induced emesis, in u.s. |
| 09/25/2001 | US6294204 Method of producing morphologically uniform microcapsules and microcapsules produced by this method |
| 09/25/2001 | US6294201 Core, comprising 15 to 35% in weight of a pharmaceutically active substance; 20 to 50% in weight of xanthan; 10 to 30% in weight of a vinyl pyrrolidone--vinyl acetate copolymer |
| 09/25/2001 | US6294200 Intermediate layer comprises hydroxypropyl methyl cellulose material suitable to form a barrier able to determine a time interval between the release of the active substance contained in the upper layer and the active substance |
| 09/25/2001 | US6294199 The dosage is provided by a bilayer tablet. |
| 09/25/2001 | US6294198 Spray-coated with a binder solution, mixed with a disintegrant, and a lubricant, and then compressed into the tablet. |
| 09/25/2001 | US6294197 Known to be effective in the treatment of congestive heart failure and reducing blood pressure. |
| 09/25/2001 | US6294196 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 09/25/2001 | US6294195 Orally administrable opioid formulations having extended duration of effect |
| 09/25/2001 | US6294194 Improving mass transfer rates, removing soluble compositions from materials. such as capsule mold lubricants, residual solvents, and contaminants from chemical and pharmaceutical containers and preparations, repeatedly modulating the |
| 09/25/2001 | US6294193 Intended to be orally ingested. |
| 09/25/2001 | US6294192 Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| 09/25/2001 | US6294191 N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| 09/25/2001 | US6294189 Containing activated charcoal that is administered to poisoning victims, wafers having a consistency emulating that of a baked cookie. |
| 09/25/2001 | US6294178 Aerosol, |
| 09/25/2001 | US6294171 Methods for treating disease states comprising administration of low levels of antibodies |
| 09/25/2001 | US6294153 Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| 09/25/2001 | US6294151 Diagnosing the infection with urease-generating bacteria, particularly helicobacter pylori. |
| 09/25/2001 | US6294045 Plaster agent and method of preparing same |
| 09/25/2001 | US6294024 Electrostatic chucks and a particle deposition apparatus therefor |
| 09/25/2001 | US6294008 Haze-free cellulose ether capsules and process for making |
| 09/23/2001 | CA2341926A1 Oral formulations of medicaments |
| 09/20/2001 | WO2001069244A2 Method for labeling individual cells |
| 09/20/2001 | WO2001068808A1 Particles containing coated living micro-organisms, and method for producing same |
| 09/20/2001 | WO2001068767A1 Dispersion comprising a non-ionic emulsifier |
| 09/20/2001 | WO2001068745A2 Liquid crystalline polymers |
| 09/20/2001 | WO2001068722A1 Hydrogel biomedical articles |
| 09/20/2001 | WO2001068721A1 Tissue bulking and coating compositions |
| 09/20/2001 | WO2001068627A1 Crystalline base of citalopram |
| 09/20/2001 | WO2001068235A1 Method for preparing colloidal particles in the form of nanocapsules |
| 09/20/2001 | WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068143A2 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068140A2 Opioid formulations |
| 09/20/2001 | WO2001068139A1 Formulation solubilizing water-insoluble agents and preparation method thereof |
| 09/20/2001 | WO2001068138A2 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068111A1 Hard gelatine capsules containing sustained-release plant extracts and method for production thereof |
| 09/20/2001 | WO2001068105A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 09/20/2001 | WO2001068100A1 Torasemide-containing pharmaceutical preparations |
| 09/20/2001 | WO2001068092A2 Glycogen phosphorylase inhibitor |
| 09/20/2001 | WO2001068082A1 Treatment and/or prevention of ocular pain |
| 09/20/2001 | WO2001068081A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd) |
| 09/20/2001 | WO2001068079A2 Viscoelastics for use in middle ear surgery |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068062A2 Packaging materials for transdermal drug delivery systems |
| 09/20/2001 | WO2001068061A1 Ultraviolet-shielding adhesive preparation |
| 09/20/2001 | WO2001068060A2 Stabilised oversaturated transdermal therapeutical matrix systems |
| 09/20/2001 | WO2001068059A1 Method and device for the production of microparticles for controlled release of water-soluble pharmaceuticals and viral vectors. application to the administration of plasmid dna and defective recombinant adenovirus |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001068057A1 Use of a copolymer for producing a pharmaceutical product for the therapy of ulcerative colitis, and pharmaceutical product provided for the inventive use |
| 09/20/2001 | WO2001068056A1 Glucocorticoids in a modified release-formulation |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068054A1 Process for the preparation of accelerated release formulations using compressed fluids |
| 09/20/2001 | WO2001068053A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/20/2001 | WO2001068052A2 Phosphate based biodegradable polymers |
| 09/20/2001 | WO2001068038A2 System for the controlled delivery of an active material to a dental site |
| 09/20/2001 | WO2001068032A1 Capsules |
| 09/20/2001 | WO2001067896A2 Method of producing oily suspensions of water-soluble vitamins |
| 09/20/2001 | WO2001067894A1 Fading inhibitors |
| 09/20/2001 | WO2001067889A1 Diabetic nutritionals |
| 09/20/2001 | WO2001067883A1 Digestable chewing gum |
| 09/20/2001 | WO2001067864A2 Topical virucidal formulation |
| 09/20/2001 | WO2001032180A3 Composition for treatment of constipation and irritable bowel syndrome |
| 09/20/2001 | WO2001032029A3 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 09/20/2001 | WO2001030366A3 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 09/20/2001 | WO2001030316A3 Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime |
| 09/20/2001 | WO2001019851A3 Opaminergic neuronal survival-promoting factors and uses thereof |
| 09/20/2001 | WO2001017503A3 Sugar compositions |
| 09/20/2001 | WO2001017479A3 Methods and compositions for preventing and treating prostate disorders |
| 09/20/2001 | WO2001015675A3 Use of docetaxel for treating hepatocellular carcinoma |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001013953A3 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist |
| 09/20/2001 | WO2001013887A3 Phospholipin gel |
| 09/20/2001 | WO2001010427A3 Use of anti-muscarinic agents for treating skin disorders |
| 09/20/2001 | WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 09/20/2001 | US20010023261 Novel composition for the transdermal administration of drugs |
| 09/20/2001 | US20010023259 Nutrients, drugs |
| 09/20/2001 | US20010023258 Mixture with carbonic anhydrase inhibitor |
| 09/20/2001 | US20010023253 Novel compound |
| 09/20/2001 | US20010023252 Paroxetine methanesulfonate |
| 09/20/2001 | US20010023245 Ophthalmic composition including a neurotrophic factor for treating optic nerve function disorders and method for treating optic nerve function disorders |
| 09/20/2001 | US20010023240 Compounds and compositions for delivering active agents |
| 09/20/2001 | US20010022975 Topical gel; containing vasodilator |
| 09/20/2001 | US20010022974 Controlling supply; insert capsules |
| 09/20/2001 | US20010022973 Pharmaceutical composition for piperidinoalkanol compounds |
| 09/20/2001 | US20010022972 Acrylic enteric coating compositions |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |